JP4541539B2 - 内因性遺伝子活性化によるエリスロポエチンの製造 - Google Patents

内因性遺伝子活性化によるエリスロポエチンの製造 Download PDF

Info

Publication number
JP4541539B2
JP4541539B2 JP2000504243A JP2000504243A JP4541539B2 JP 4541539 B2 JP4541539 B2 JP 4541539B2 JP 2000504243 A JP2000504243 A JP 2000504243A JP 2000504243 A JP2000504243 A JP 2000504243A JP 4541539 B2 JP4541539 B2 JP 4541539B2
Authority
JP
Japan
Prior art keywords
epo
human
gene
cells
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2000504243A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001511343A (ja
Inventor
アン スターン
ミハエル ブラント
コンラッド ホノルド
ヨハンヌ オーエル
ハンス コール
Original Assignee
ロシュ ダイアグノスティックス ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27217987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4541539(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE1997153681 external-priority patent/DE19753681A1/de
Priority claimed from US09/113,692 external-priority patent/US6548296B1/en
Application filed by ロシュ ダイアグノスティックス ゲーエムベーハー filed Critical ロシュ ダイアグノスティックス ゲーエムベーハー
Publication of JP2001511343A publication Critical patent/JP2001511343A/ja
Application granted granted Critical
Publication of JP4541539B2 publication Critical patent/JP4541539B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2000504243A 1997-07-23 1998-07-22 内因性遺伝子活性化によるエリスロポエチンの製造 Expired - Lifetime JP4541539B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP97112640 1997-07-23
DE1997153681 DE19753681A1 (de) 1997-12-03 1997-12-03 Erythropoietin mit hoher spezifischer Aktivität
US19753681.6 1998-07-10
US09/113,692 1998-07-10
US09/113,692 US6548296B1 (en) 1997-07-23 1998-07-10 Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
US97112640.4 1998-07-10
PCT/EP1998/004590 WO1999005268A1 (de) 1997-07-23 1998-07-22 Herstellung von erythropoietin durch endogene genaktivierung

Publications (2)

Publication Number Publication Date
JP2001511343A JP2001511343A (ja) 2001-08-14
JP4541539B2 true JP4541539B2 (ja) 2010-09-08

Family

ID=27217987

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000504243A Expired - Lifetime JP4541539B2 (ja) 1997-07-23 1998-07-22 内因性遺伝子活性化によるエリスロポエチンの製造

Country Status (13)

Country Link
EP (1) EP0986644B1 (pt)
JP (1) JP4541539B2 (pt)
CN (1) CN1151258C (pt)
AT (1) ATE341625T1 (pt)
AU (1) AU754619B2 (pt)
BR (1) BRPI9811031B8 (pt)
CA (1) CA2298015C (pt)
DE (1) DE59813758D1 (pt)
DK (1) DK0986644T3 (pt)
ES (1) ES2273434T3 (pt)
TR (1) TR200000175T2 (pt)
TW (1) TW574372B (pt)
WO (1) WO1999005268A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
JP4220125B2 (ja) 1997-12-03 2009-02-04 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 高い比活性を有するエリスロポエチン
WO2003048348A2 (en) 2001-12-07 2003-06-12 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7259146B2 (en) 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
WO2002064085A2 (en) 2001-02-02 2002-08-22 Ortho-Mcneil Pharmaceutical, Inc. Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
KR100493703B1 (ko) * 2001-10-30 2005-06-02 신풍제약주식회사 동물세포용 재조합 벡터 및 에리트로포이에틴을 대량으로 생산하기 위한 동물세포용 발현벡터
US6818613B2 (en) 2001-11-07 2004-11-16 Ortho-Mcneil Pharmaceutical, Inc. Aqueous sustained-release formulations of proteins
BR0214557A (pt) 2001-11-28 2006-06-06 Ortho Mcneil Pharm Inc regime de dosagem de eritropoietina para o tratamento de anemia
US7129267B2 (en) 2002-03-11 2006-10-31 Janssen Pharmaceutica N.V. Methods for SHP1 mediated neuroprotection
EP1520008B1 (en) 2002-07-09 2012-09-05 Baxter International Inc. Animal protein free media for cultivation of cells
EA008670B1 (ru) 2003-05-09 2007-06-29 Круселл Холланд Б.В. Культуры e1-иммортализованных клеток и способы их культивирования с целью повышения выхода их продукции
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
PL3121266T3 (pl) 2006-01-04 2020-07-13 Baxalta Incorporated Wolne od oligopeptydów pożywki do hodowli komórkowej
CN101062407A (zh) 2006-04-29 2007-10-31 中国科学院上海生命科学研究院 促红细胞生成素在预防或治疗视网膜损伤中的用途
EP2134862A4 (en) * 2007-03-12 2011-04-20 Univ Utah Res Found COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DIABETIC MICROVASCULAR COMPLICATIONS
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
EP2334699B1 (en) * 2008-09-23 2013-09-11 F. Hoffmann-La Roche AG Purification of erythropoietin
KR101647164B1 (ko) 2008-09-26 2016-08-09 암브룩스, 인코포레이티드 변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
CN104059128B (zh) * 2010-09-17 2016-08-03 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用
CN102659928B (zh) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用
CN102659927B (zh) * 2010-09-17 2014-02-05 上海凯茂生物医药有限公司 一种人工合成的信号肽及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL77081A (en) * 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
JPS62171696A (ja) * 1986-01-23 1987-07-28 Sumitomo Chem Co Ltd ヒトエリスロポエチンの製造方法
JPS62265992A (ja) * 1986-05-12 1987-11-18 Ajinomoto Co Inc ヒト細胞を用いる有用物質の製造方法
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
JPH01165393A (ja) * 1987-12-21 1989-06-29 Sumitomo Chem Co Ltd 組換えヒトエリスロポエチンの精製方法
EP0747485B1 (en) * 1989-11-06 1998-12-02 Cell Genesys, Inc. Production of proteins using homologous recombination
ES2151463T5 (es) * 1989-12-22 2012-10-29 Merck Serono Sa Constructos de ADN para la activación y la modificación de la expresión de genes endógenos
US6270989B1 (en) * 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
PT101031B (pt) * 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
TW402639B (en) * 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
IL118201A (en) * 1995-05-11 2004-12-15 Roche Diagnostics Gmbh Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof

Also Published As

Publication number Publication date
CA2298015A1 (en) 1999-02-04
JP2001511343A (ja) 2001-08-14
TR200000175T2 (tr) 2001-01-22
DE59813758D1 (de) 2006-11-16
BRPI9811031A (pt) 2000-08-08
BRPI9811031B1 (pt) 2011-10-04
AU754619B2 (en) 2002-11-21
CN1151258C (zh) 2004-05-26
BRPI9811031B8 (pt) 2021-07-06
CN1265143A (zh) 2000-08-30
TW574372B (en) 2004-02-01
ES2273434T3 (es) 2007-05-01
ATE341625T1 (de) 2006-10-15
EP0986644B1 (de) 2006-10-04
EP0986644A1 (de) 2000-03-22
WO1999005268A1 (de) 1999-02-04
DK0986644T3 (da) 2007-01-29
CA2298015C (en) 2015-01-27
AU8978698A (en) 1999-02-16

Similar Documents

Publication Publication Date Title
JP4541539B2 (ja) 内因性遺伝子活性化によるエリスロポエチンの製造
US6391633B1 (en) Production of erythropoietin by endogenous gene activation
CA1341361C (en) Human erythropoietin gene: high level expression in stably transfected mammalian cells
KR0157983B1 (ko) 아미드화 효소 발현계
CA1336329C (en) Fusion proteins, a process for their preparation and their use
US5359033A (en) Cleaved dimers of mullerian inhibiting substance-like polypeptides
JP6047524B2 (ja) 内因性遺伝子の活性化によるヒト蛋白質の生産のためのヒト細胞株の同定
IE893984L (en) TGF-ß1/ß2: A NOVEL CHIMERIC TRANSFORMING GROWTH FACTOR-BETA
US6395484B1 (en) Identification of human cell lines for the production of human proteins by endogenous gene activation
US6555373B1 (en) Methods for identifying human cell lines useful for endogenous gene activation isolated human cell lines identified thereby, and uses thereof
AU776280B2 (en) Production of erythropoietin by endogenous gene activation
MXPA00000745A (en) Production of erythropoietin by endogenous gene activation
JPS6137099A (ja) 蛋白質の製造法
KR20010022127A (ko) 상동 재조합에 의해 사람 세포에서 사람 변이 단백질을생성시키는 방법
MXPA00000677A (en) Identification of human cell lines for the production of human proteins by endogenous gene activation
MXPA00003804A (es) Seleccion positiva- negativa durante la recombinacion homologa

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080222

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080422

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080516

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080523

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080617

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080624

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080717

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091228

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100405

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100602

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100624

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130702

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term